Our advanced equipment and extensive professional expertise make available a wide range of labeling services and radioisotopes tailored to meet your needs.
GLUCOTOPE(FDG), a glucose analog labeled with fluorine-18, is the most commonly used radiopharmaceutical in PET imaging. It concentrates in cells that rely upon glucose as an energy source or in cells whose dependence on glucose increases under pathophysiological conditions. It has a half-life of 109.7 minutes.
Clinical indications calling for the use of FDG injection
and PET imaging include assessment of abnormal glucose metabolism to assist
in:
--the evaluation of malignancy in patients with known or suspected abnormalities
found by other testing modalities or in patients with an existing diagnosis
of cancer
--the identification of left ventricular myocardium with residual glucose
metabolism and reversible loss of systolic function and
--the identification of regions of abnormal glucose metabolism associated
with the foci of epileptic seizures.
AMMONIA N 13 is rapidly distributed to all organs of the body after intravenous administration.It is indicated for PET imaging of the myocardium under rest or pharmacological stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. It has a physical half-life of 9.96 minutes.
SODIUM
FLUORIDE F 18 is a positron-emitting radiopharmaceutical
that is used for diagnostic purposes in conjunction with PET imaging.
Sodium Fluoride is indicated in PET imaging to define areas of bone metastasis
and altered osteogenic activity. Fluorine F 18 decays with a physical
half-life of 109.7 minutes.
